2025
Validity of Diagnostic Codes and Laboratory Tests to Identify Cholangiocarcinoma and Its Subtypes
Ferrante N, Hubbard R, Weinfurtner K, Mezina A, Newcomb C, Furth E, Bhattacharya D, Njei B, Taddei T, Singal A, Hoteit M, Park L, Kaplan D, Re V. Validity of Diagnostic Codes and Laboratory Tests to Identify Cholangiocarcinoma and Its Subtypes. Pharmacoepidemiology And Drug Safety 2025, 34: e70154. PMID: 40328444, PMCID: PMC12055315, DOI: 10.1002/pds.70154.Peer-Reviewed Original ResearchConceptsPositive predictive valueVeterans Health AdministrationExtrahepatic cholangiocarcinomaValidity of diagnostic codesInternational Classification of Diseases for OncologyUS Veterans Health AdministrationConfidence intervalsPharmacoepidemiological studiesICD-O-3Days of diagnosisVA dataHealth AdministrationIntrahepatic cholangiocarcinomaDiagnostic codesHistology codesCholangiocarcinomaUnique patientsInclusion criteriaCholangiocarcinoma subtypesTopography codesPredictive valuePatientsEvaluate medicationsSubtypesEvaluate determinantsOlaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
Cecchini M, Pilat M, Uboha N, Azad N, Cho M, Davis E, Ahnert J, Tinoco G, Shapiro G, Khagi S, Powers B, Spencer K, Groisberg R, Drappatz J, Chen L, Das B, Bao X, Li J, Narayan A, Vu D, Patel A, Niger M, Doroshow D, Durecki D, Boerner S, Bindra R, Ivy P, Shyr D, Shyr Y, LoRusso P. Olaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial. Cancer 2025, 131: e35755. PMID: 39917990, PMCID: PMC11949439, DOI: 10.1002/cncr.35755.Peer-Reviewed Original ResearchConceptsProgression-free survivalHomologous recombination deficiencyClinical benefitNational Cancer InstituteIDH inhibitorsMedian progression-free survivalAccumulation of 2-hydroxyglutaratePhase 2 clinical trialIsocitrate dehydrogenase inhibitorsMedian overall survivalSingle-agent activityNovel combination therapiesEnhance patient selectionSubgroup of patientsOverall survivalOpen-labelCombination therapyIDH mutationsPatient selectionRecombination deficiencySolid tumorsTumor progressionClinical trialsOlaparibCholangiocarcinoma
2024
Beyond cholangiocarcinoma: imaging features of mimicking pathologies in the biliary tract
Khasawneh H, O’Brien C, Czeyda-Pommersheim F, Qayyum A, Miller F, Arif Tiwari H, Paspulati R, Kierans A. Beyond cholangiocarcinoma: imaging features of mimicking pathologies in the biliary tract. Abdominal Radiology 2024, 50: 2928-2943. PMID: 39710762, DOI: 10.1007/s00261-024-04749-z.Peer-Reviewed Original ResearchMalignant conditionsOverlap of imaging findingsDiagnosis of cholangiocarcinomaPrimary malignancyDifferentiate cholangiocarcinomaHistopathological confirmationImaging findingsMorphological subtypesDifferential diagnosisBiliary tractHeterogeneous diseaseDiagnostic accuracyPatient managementCholangiocarcinomaAccurate diagnosisHepatobiliary systemImage featuresPeriductal-infiltratingClinical practiceImaging characteristicsDiagnosisvon Meyenburg complexes are more frequently associated with cholangiocarcinoma
Jain D, Khandakar B, Ni P, Kenney B, Qin L, Deshpande V, Fiel M. von Meyenburg complexes are more frequently associated with cholangiocarcinoma. Journal Of Clinical Pathology 2024, 78: 300-306. PMID: 38729770, DOI: 10.1136/jcp-2024-209572.Peer-Reviewed Original ResearchVon Meyenburg complexesHilar CCHepatic resectionCC casesChronic viral hepatitis BAssociated liver disordersMeyenburg complexesProgress to cholangiocarcinomaDysplasia/carcinoma in situMetastatic colon carcinomaViral hepatitis BCases of CCBile duct adenomaPolycystic kidney diseaseAssociated with cholangiocarcinomaBenign lesionsCryptogenic cirrhosisHepatitis BBiliary diseaseColon carcinomaMiscellaneous disordersKidney diseaseLiver diseaseCholangiocarcinomaLiver disorders
2023
Platinum Sensitivity in IDH1/2 Mutated Intrahepatic Cholangiocarcinoma: Not All “BRCAness” Is Created Equal
Doroshow D, Wei W, Mehrotra M, Sia D, Eder J, Bindra R, Houldsworth J, LoRusso P, Walther Z. Platinum Sensitivity in IDH1/2 Mutated Intrahepatic Cholangiocarcinoma: Not All “BRCAness” Is Created Equal. Cancer Investigation 2023, 41: 646-655. PMID: 37505929, DOI: 10.1080/07357907.2023.2242957.Peer-Reviewed Original ResearchConceptsClinical benefit rateIntrahepatic cholangiocarcinomaPlatinum sensitivityUnresectable intrahepatic cholangiocarcinomaObjective response rateMulticenter retrospective studyHomologous recombination repairDefective homologous recombination (HR) repairPrimary endpointPlatinum chemotherapyRetrospective studyPreclinical dataBenefit rateWildtype tumorsResponse rateMT tumorsWT diseasePatientsGene defectsCholangiocarcinomaTumorsSolid-Tubulocystic carcinoma: A new variant of intrahepatic cholangiocarcinoma
González I, Luo W, Zhang X. Solid-Tubulocystic carcinoma: A new variant of intrahepatic cholangiocarcinoma. World Journal Of Hepatology 2023, 15: 897-903. PMID: 37547028, PMCID: PMC10401414, DOI: 10.4254/wjh.v15.i7.897.Peer-Reviewed Original ResearchVariant of intrahepatic cholangiocarcinomaIntrahepatic cholangiocarcinomaExpression of inhibinMetastatic hepatic neoplasmsCystic growth patternDiagnostic work-upRecurrent gene fusionsModerate amount of eosinophilic cytoplasmGene fusionsAmount of eosinophilic cytoplasmImmunohistochemical profileClinicopathological featuresEosinophilic cytoplasmBiliary markersTumor cellsMorphologic spectrumHepatic massHepatic neoplasmsWork-upHepatic carcinomaVariantsYoung womenInhibinTumorCholangiocarcinomaSAT-283 Intrahepatic cholangiocarcinoma developing in patients with metabolic syndrome is characterized by Osteopontin overexpression in the tumor stroma
Cadamuro M, Sarcognato S, Camerotto R, Girardi N, Lasagni A, Zanus G, Cillo U, Gringeri E, Morana G, Strazzabosco M, Campello E, Simioni P, Guido M, Fabris L. SAT-283 Intrahepatic cholangiocarcinoma developing in patients with metabolic syndrome is characterized by Osteopontin overexpression in the tumor stroma. Journal Of Hepatology 2023, 78: s564-s565. DOI: 10.1016/s0168-8278(23)01358-2.Peer-Reviewed Original ResearchRecent Advances in the Management of Primary Sclerosing Cholangitis
Assis D, Bowlus C. Recent Advances in the Management of Primary Sclerosing Cholangitis. Clinical Gastroenterology And Hepatology 2023, 21: 2065-2075. PMID: 37084929, DOI: 10.1016/j.cgh.2023.04.004.Peer-Reviewed Original ResearchConceptsChronic cholestatic liver diseasePrimary sclerosing cholangitisInflammatory bowel diseasePrognostication of patientsCholestatic liver diseaseSclerosing cholangitisBowel diseaseLiver failureClinical featuresLiver diseaseMedical managementBiliary treeComplex pathophysiologyEffective therapyPharmacologic agentsRare natureCurrent conceptsDiseaseCholangitisFurther studiesCholangiocarcinomaPatientsPathophysiologyTherapyPrognosticationMitochondrial calcium signaling in cholangiocarcinoma
Loyola-Machado A, Guerra M, Nathanson M. Mitochondrial calcium signaling in cholangiocarcinoma. Hepatoma Research 2023, 9: null-null. DOI: 10.20517/2394-5079.2023.28.Peer-Reviewed Original ResearchPrimary liver cancerNew pharmacological agentsPathogenesis of cholangiocarcinomaMitochondrial Ca2Liver cancerCholangiocarcinomaPharmacological agentsIntracellular Ca2Molecular alterationsDruggable targetsER-mitochondrial contact sitesCancer cellsKey regulatory moleculesMetabolic reprogramingReceptor familyMitochondrial healthMitochondrial calciumEnergy metabolismCell deathPathways of interestLatest findingsTreatmentCa2Regulatory moleculesContact sites
2022
An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma
Madoff DC, Abi-Jaoudeh N, Braxton D, Goyal L, Jain D, Odisio BC, Salem R, Schattner M, Sheth R, Li D. An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma. The Oncologist 2022, 27: 884-891. PMID: 35925597, PMCID: PMC9526481, DOI: 10.1093/oncolo/oyac139.Peer-Reviewed Original ResearchConceptsIntrahepatic cholangiocarcinomaBiomarker testingMultidisciplinary teamImage-guided liver biopsyMetastatic intrahepatic cholangiocarcinomaEvidence-based guidelinesIntrahepatic biliary treeNext-generation sequencingActionable genetic alterationsTreatment landscapeLiver biopsyMedical oncologistsInterventional oncologistsPoor prognosisAggressive malignancyBiliary treeTissue acquisitionBiopsy methodImaging modalitiesDesmoplastic natureGenetic alterationsTissue collectionNeedle choicePrecision medicineCholangiocarcinomaTranslational Value of Tumor-Associated Lymphangiogenesis in Cholangiocarcinoma
Cadamuro M, Romanzi A, Guido M, Sarcognato S, Cillo U, Gringeri E, Zanus G, Strazzabosco M, Simioni P, Villa E, Fabris L. Translational Value of Tumor-Associated Lymphangiogenesis in Cholangiocarcinoma. Journal Of Personalized Medicine 2022, 12: 1086. PMID: 35887583, PMCID: PMC9324584, DOI: 10.3390/jpm12071086.Peer-Reviewed Original ResearchTumor-associated lymphangiogenesisTumor-draining lymph nodesTargetable genetic alterationsNovel therapeutic targetCholangiocarcinoma invasivenessLiver transplantationLiver resectionLymph nodesCurative potentialPrimary tumorAvailable treatmentsSurgical proceduresLymphatic metastasisTherapeutic targetTumor microenvironmentTranslational valueMolecular profilingGenetic alterationsLymphangiogenesisCholangiocarcinomaMetastasisProgressionCurrent knowledgeRecent findingsMolecular mechanismsInflammatory pathways and cholangiocarcioma risk mechanisms and prevention
Cadamuro M, Strazzabosco M. Inflammatory pathways and cholangiocarcioma risk mechanisms and prevention. Advances In Cancer Research 2022, 156: 39-73. PMID: 35961707, PMCID: PMC10916841, DOI: 10.1016/bs.acr.2022.02.001.Peer-Reviewed Original ResearchConceptsDevelopment of cholangiocarcinomaNonalcoholic fatty liver diseaseAdequate therapeutic treatmentPrimary sclerosing cholangitisFatty liver diseasePro-inflammatory mechanismsMain risk factorsProdromal diseaseSclerosing cholangitisCaroli's diseaseMetabolic syndromeChronic cholangiopathiesLiver diseasePoor prognosisInflammatory pathwaysBiliary treeCCA developmentRisk factorsImmune responseImmunological responseTherapeutic targetCholangiocarcinomaFluke infestationRole of cellExtrahepatic areasTumor microenvironment and immunology of cholangiocarcinoma
Cadamuro M, Fabris L, Zhang X, Strazzabosco M. Tumor microenvironment and immunology of cholangiocarcinoma. Hepatoma Research 2022, 8: null-null. PMID: 39301518, PMCID: PMC11412615, DOI: 10.20517/2394-5079.2021.140.Peer-Reviewed Original Research
2021
Lipiodol Deposition and Washout in Primary and Metastatic Liver Tumors After Chemoembolization
Nezami N, VAN Breugel JMM, Konstantinidis M, Chapiro J, Savic LJ, Miszczuk MA, Rexha I, Lin M, Hong K, Georgiades C. Lipiodol Deposition and Washout in Primary and Metastatic Liver Tumors After Chemoembolization. In Vivo 2021, 35: 3261-3270. PMID: 34697157, PMCID: PMC8627740, DOI: 10.21873/invivo.12621.Peer-Reviewed Original ResearchConceptsConventional trans-arterial chemoembolizationTrans-arterial chemoembolizationNeuroendocrine tumorsColorectal carcinomaIntrahepatic cholangiocarcinomaLipiodol depositionWashout rateContrast-enhanced magnetic resonanceMetastatic liver tumorsColorectal carcinoma tumorsLiver metastasesHepatic metastasesTumor responseTarget lesionsRetrospective analysisLiver tumorsSmall tumorsChemoembolizationCarcinoma tumorsTumorsExponential washoutCarcinomaTomography imagingWashoutCholangiocarcinomaUnmet needs in basic and translational research in Cholangiocarcinoma
Cadamuro M, Macias R, Strain A, Strazzabosco M, Simioni P, Marin J, Fabris L. Unmet needs in basic and translational research in Cholangiocarcinoma. Liver International Communications 2021, 3: 5-16. DOI: 10.1002/lci2.39.Peer-Reviewed Original ResearchTranslational researchManagement of cholangiocarcinomaTumor-restraining functionsSystematic literature searchCCA managementPoor prognosisExtrahepatic cholangiocarcinomaDeep molecular phenotypingConsensus statementEnigmatic diseaseActionable mutationsCholangiocarcinomaAccurate biomarkersTumor microenvironmentLiterature searchExperimental modelEarly detectionMarked heterogeneityDiseaseMolecular phenotypingWide heterogeneityFurther studiesTumorsMolecular characterization studiesComplex roleRole of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma
Rexha I, Laage-Gaupp F, Chapiro J, Miszczuk MA, van Breugel JMM, Lin M, Konstantinidis M, Duran R, Gebauer B, Georgiades C, Hong K, Nezami N. Role of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma. Scientific Reports 2021, 11: 9337. PMID: 33927226, PMCID: PMC8085245, DOI: 10.1038/s41598-021-88426-x.Peer-Reviewed Original ResearchConceptsTotal tumor volumeConventional transarterial chemoembolizationTumor diameterIntrahepatic cholangiocarcinomaOverall survivalTumor areaICC patientsTumor volumeHigh tumor burden groupTumor analysisOS of patientsHazard ratioTransarterial chemoembolizationTumor burdenBurden groupConventional chemoembolizationHTB groupRetrospective analysisPatientsSurvival curvesMultivariate analysisChemoembolizationCholangiocarcinomaETVBaseline imagesCholangiocarcinoma
Lasagni A, Strazzabosco M, Guido M, Fabris L, Cadamuro M. Cholangiocarcinoma. 2021, 231-259. DOI: 10.1007/978-3-030-65908-0_14.Peer-Reviewed Original ResearchTypes of cholangiocarcinomaDifferent epithelial cancersLiver transplantationGastrointestinal malignanciesMost patientsSurgical resectionRich tumor microenvironmentCurative treatmentChronic inflammationNegative marginsAggressive tumorsBiliary treeRare cancersRisk factorsCholangiocarcinomaAdvanced stageEpithelial cancersAnatomical locationTumor microenvironmentPatientsDistinct cancersCancerDesmoplastic natureMultimodal approachLaboratory tests
2020
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Ilyas S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology & Hepatology 2020, 17: 557-588. PMID: 32606456, PMCID: PMC7447603, DOI: 10.1038/s41575-020-0310-z.Peer-Reviewed Original ResearchConceptsPrimary liver cancerExpert consensus statementCancer-related deathCell of originBiliary malignant tumorsStudy of CholangiocarcinomaGastrointestinal malignanciesHistological confirmationAvailable therapiesBiliary treeNew diagnostic toolsSilent presentationPatient outcomesConsensus statementMalignant tumorsLiver cancerCholangiocarcinomaAggressive natureAlarming mortalityCurrent diagnosisMolecular alterationsNon-invasive approachTumorsDiagnostic toolTherapyGenomics and Interventional Oncology in Primary Liver Cancer
Slovak R, Dendy Case M, Kim H. Genomics and Interventional Oncology in Primary Liver Cancer. Digestive Disease Interventions 2020, 04: 053-059. DOI: 10.1055/s-0040-1708533.Peer-Reviewed Original ResearchPrimary liver cancerLiver cancerInterventional oncologyForms of malignancyOncologic careInterventional oncologistsIntrahepatic cholangiocarcinomaHepatocellular carcinomaIndividual tumorsCancerPrecision medicineOncologyPersonalized medicineRadiogenomics researchRadiomicsMedicineCholangiocarcinomaCarcinomaMalignancyOncologistsTumorsCareType 3 Inositol 1,4,5‐Trisphosphate Receptor Is Increased and Enhances Malignant Properties in Cholangiocarcinoma
Ueasilamongkol P, Khamphaya T, Guerra MT, Rodrigues M, Gomes DA, Kong Y, Wei W, Jain D, Trampert DC, Ananthanarayanan M, Banales JM, Roberts LR, Farshidfar F, Nathanson MH, Weerachayaphorn J. Type 3 Inositol 1,4,5‐Trisphosphate Receptor Is Increased and Enhances Malignant Properties in Cholangiocarcinoma. Hepatology 2020, 71: 583-599. PMID: 31251815, PMCID: PMC6934938, DOI: 10.1002/hep.30839.Peer-Reviewed Original ResearchConceptsType 3 inositolCCA cellsIntracellular calcium ionsPathogenesis of malignanciesCCA cell linesCommon malignancyPoor prognosisTrisphosphate receptorMalignant featuresMitochondrial CaITPR3 expressionCholangiocarcinomaRegions of ERMalignant propertiesCCA samplesCell proliferationCholangiocytesEndoplasmic reticulumType of tissueMalignancyCell linesITPR3PathogenesisCell deathCell migration
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply